A team of researchers is turning to AI to help fill the urgent need for effective therapeutics for COVID-19. Using previously known ligands for 65 human proteins known to interact with SARS-CoV-2 proteins, a machine learning model was trained to predict inhibitory activity. After screening millions of chemicals, some of which are already approved for use in humans, hundreds of potential drugs were identified that could help treat COVID-19.
A team of researchers led by neuroscientists at Harvard Medical School used acupuncture to dampen potentially fatal cytokine storm inflammatory responses in mice with experimentally induced systemic inflammation. The studies showed how treatment activated different signaling pathways that triggered either a pro-inflammatory or an anti-inflammatory response, dependent upon where on the body acupuncture was applied, and the timing and intensity of treatment.
Over the past decade, scientists have been adopting strategies that limit the availability of serine and glycine—amino acids that are critical for cancer progression—as potential cancer therapies. Now researchers from the University of California, San Diego, and Salk Institute for Biomedical Studies have adopted a new approach by focusing on serine metabolism. Their new approach has led to a decrease in tumor progression in mice and highlights the complexity of metabolism.
Scientists have taken the first step toward a new way of treating gastric wounds by using a microrobot combined with the new concept of "in situ in vivo bioprinting" to carry out tissue repair inside the body. Their study establishes proof-of-concept for this new method in the field of bioprinting.
Researchers at the University of Birmingham and Newcastle University have identified and characterized key enzymes used by bacteria to break down mucus in the gut, which may be used as a helpful biomarker for intestinal diseases. Their findings open a door of understanding the complex relationships at work in the gut.
NIAID and Moderna are now conducting an approximately 30,000-patient Phase III trial of mRNA-1273, for which enrollment is on track to be completed in September, Moderna said.
An assessment of host erythrocyte signaling during infection with Plasmodium falciparum, the causative agent of malaria, suggests that targeting enzymes from the human host, rather than from the pathogen itself, could offer effective treatment. The study provides a proof of concept that human signaling kinases represent attractive targets for antimalarial intervention.
Studies by researchers at Washington University School of Medicine in St. Louis have shown how the effects of a standard immunotherapy drug can be enhanced by blocking a protein called TREM2, resulting in the complete elimination of tumors. The results point to a potential new way to render immunotherapy effective for greater numbers of cancer patients. Investigators suggest that if further preclinical work yields positive results, it may be possible to move into clinical trials relatively easily because there are already a number of antibodies available.
The deal would add to Bayer’s pipeline KaNDy’s lead compound NT-814, a potential first-in-class, oral once-daily, dual mechanism neurokinin-1,3 receptor antagonist that is expected to launch a Phase III trial next year.
Advanced analytical methods and improved staff training programs are needed to take full advantage of digital manufacturing.
Please wait while you are redirected to the right page...